logo-loader

Lannett Company gets FDA nod for generic flu drug

Last updated: 07:54 16 Jun 2017 EDT, First published: 02:54 16 Jun 2017 EDT

flu patient
Its the first product to clear FDA approval after pharmacokinetic by DarmanTest

Generic drug manufacturer Lannett Company Inc (NYSE: LCI) is looking forward to the next flu season after securing approval for a new product, comparable to the Symmetrel branded treatment.

The Food and Drug Administration (FDA) has signed off Lannett’s Amantadine Hydrochloride Capsules, described as being the ‘therapeutic equivalent’ of the reference standard drug which is produced by Sandoz Pharmaceuticals.

"While this approval comes too late to benefit fiscal 2017, which ends later this month, we expect to launch the product in time for the coming flu season,” said Arthur Bedrosian, Lannett chief executive.

He also highlighted that the approval was approved in 15 months, and it represents the first product to be approved following bio-equivalency study at the company’s pharmacokinetic subsidiary, DarmanTest Laboratories.  

Australian Strategic Materials signs US$600 million LoI

Rowena Smith, CEO and managing director of Australian Strategic Materials Ltd (ASX:ASM, OTC:ASMMF), joins Jonathan Jackson in the Proactive studio to discuss the company’ s Dubbo Project, in Central West New South Wales. This project aims to extract and process critical minerals and rare earth...

3 hours, 56 minutes ago